December 15, 2014
Kyowa Kirin President Nobuo Hanai Revving up its drive to establish itself as a global specialty pharma, Kyowa Hakko Kirin has recently inked a series of collaboration deals on its anti-CCR4 humanized antibody Poteligeo (mogamulizumab). We spoke with President and...read more